PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29518977-4	2018	By combining statistical methods with available gene annotations and without a previously defined hypothesis HRas, MAPK14 (p38), CCL2, DOK1 and PTK2B were identified as genes possibly relevant for cisplatin resistance.	Cisplatin	197-206	C-C motif chemokine ligand 2	Homo sapiens	129-133	
32200039-5	2020	The chemokine expression of CXCL1, CXCL2, and CCL2 increased in cisplatin-resistant cells compared to those in their parent strains.	Cisplatin	64-73	C-C motif chemokine ligand 2	Homo sapiens	46-50	
29518977-6	2018	HRas, p38, CCL2, DOK1, PTK2B and JNK3 were integrated into a model of resistance-associated signalling alterations describing differential gene and protein expression between cisplatin-sensitive and -resistant cells in reaction to cisplatin exposure.	Cisplatin	175-184	C-C motif chemokine ligand 2	Homo sapiens	11-15	
29518977-6	2018	HRas, p38, CCL2, DOK1, PTK2B and JNK3 were integrated into a model of resistance-associated signalling alterations describing differential gene and protein expression between cisplatin-sensitive and -resistant cells in reaction to cisplatin exposure.	Cisplatin	231-240	C-C motif chemokine ligand 2	Homo sapiens	11-15	
29231123-12	2018	This minireview highlights several proteins (kidney injury molecule-1, beta-2-microglobulin, neutrophil gelatinase-associated lipocalin, calbindin, monocyte chemotactic protein-1, trefoil factor 3) with the greatest promise for detecting cisplatin-induced acute kidney injury in humans.	Cisplatin	238-247	C-C motif chemokine ligand 2	Homo sapiens	148-196	
26124338-7	2015	Addition of MCP1 to cisplatin, docetaxel and cilengitide increased efficacy of cytostatics in inhibition of colony formation, whereas those with temsirolimus were increased by anti-MCP1 that when applied alone failed to modulate colony formation.	Cisplatin	20-29	C-C motif chemokine ligand 2	Homo sapiens	12-16	
26407820-0	2015	Urinary kidney injury molecule-1 and monocyte chemotactic protein-1 are noninvasive biomarkers of cisplatin-induced nephrotoxicity in lung cancer patients.	Cisplatin	98-107	C-C motif chemokine ligand 2	Homo sapiens	37-67	
26407820-9	2015	CONCLUSIONS: Urinary KIM-1 and MCP-1, either alone or in combination, may represent biomarkers of cisplatin-induced AKI in lung cancer patients.	Cisplatin	98-107	C-C motif chemokine ligand 2	Homo sapiens	31-36	
28356286-5	2017	With early treatment, cisplatin nephrotoxicity was attenuated as evidenced by decreased blood urea nitrogen (BUN) and reduced apoptosis and tubular injury scores on day 3 Early treatment resulted in downregulation of intrarenal monocyte chemotactic protein-1 and IL-6 expression and upregulation of IL-10 and VEGF expression.	Cisplatin	22-31	C-C motif chemokine ligand 2	Homo sapiens	228-258	
21187454-4	2010	The CCL2 gene expression evaluated by RT-PCR was investigated in relation to chemo-response/clinical outcomes in the OC patients and to sensitivity to cisplatin/paclitaxel in the OCCLs.	Cisplatin	151-160	C-C motif chemokine ligand 2	Homo sapiens	4-8	
24211271-8	2014	Additionally, cisplatin showed a marked pro-inflammatory response as evidenced by significant increase in tissue levels of IL-1beta, TNF-alpha, NF-kB, iNOS, ICAM-1 and MCP-1.	Cisplatin	14-23	C-C motif chemokine ligand 2	Homo sapiens	168-173	
21187454-9	2010	The cells expressing higher levels of CCL2 were more sensitive to paclitaxel and cisplatin as compared to those lines expressing lower levels of this chemokine.	Cisplatin	81-90	C-C motif chemokine ligand 2	Homo sapiens	38-42	
14681721-0	2004	hTERT-promoter-based tumor-specific expression of MCP-1 effectively sensitizes cervical cancer cells to a low dose of cisplatin.	Cisplatin	118-127	C-C motif chemokine ligand 2	Homo sapiens	50-55	
18697197-4	2008	Treatment of tumor cells with doxorubicin and cisplatin resulted in a substantial increase in the production of IL-6, CXCL8, CCL2, CCL5, BFGF, G-CSF and VEGF.	Cisplatin	46-55	C-C motif chemokine ligand 2	Homo sapiens	125-129	
14681721-7	2004	However, when combined with a suboptimal low dose of cisplatin, tumor formation was obviously reduced in clones transduced with MCP-1, but not in control clones.	Cisplatin	53-62	C-C motif chemokine ligand 2	Homo sapiens	128-133	
14681721-9	2004	These findings suggest that MCP-1 expression sensitizes cervical cancer cells to an otherwise ineffective low dose of cisplatin, possibly by inducing the migration of macrophages to eradicate tumor cells.	Cisplatin	118-127	C-C motif chemokine ligand 2	Homo sapiens	28-33	
10408835-6	1999	Further support for mismatch repair being involved in sensitivity of the minor groove alkylators is that two cisplatin-resistant sublines of the human ovarian adenocarcinoma cell line A2780 (A2780/CP70 and A2780/MCP-1) are defective in hMLH1 expression and are more resistant to these agents than the parental mismatch repair proficient cells.	Cisplatin	109-118	C-C motif chemokine ligand 2	Homo sapiens	206-217	
34499269-0	2021	EGR1-CCL2 Feedback Loop Maintains Epithelial-Mesenchymal Transition of Cisplatin-Resistant Gastric Cancer Cells and Promotes Tumor Angiogenesis.	Cisplatin	71-80	C-C motif chemokine ligand 2	Homo sapiens	5-9	
35533545-9	2022	The results suggested that ameliorating cisplatin-induced AKI actions of 9b was involved in downregulation of TNF-alpha, IL-1beta, IL-6, and MCP-1, inhibition of NF-kB activation, and reduction of GRPR and oxidative stress level.	Cisplatin	40-49	C-C motif chemokine ligand 2	Homo sapiens	141-146